Preliminary results from testing conducted by the European Center for Disease Control and Prevention (ECDC) indicate that some strains of the influenza A circulating in Europe this season are unaffected by Roche's antiviral Tamiflu (oseltamivir). Of the 148 H1N1 viral variants isolated between November and December of 2007 by the European Union's VIRGIL network, 19 have shown some degree of resistance.
The majority of the positive samples, 12 of the 19, are derived from the 16 isolates submitted by Norwegian authorities, indicating that viruses circulating in the country have a high degree of resistance to Tamiflu.
Senior influenza experts told The Canadian Press that, because none of the positive samples were from patients that had received Tamiflu, the findings are "the first clear evidence that influenza A (H1N1) virus with the H274Y mutation [which allows that to resist Tamiflu] can readily transmit between individuals."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze